Protocol Ledger

NCT06016842 · Phase III · RECRUITING

A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis

Interventional Phase III clinical trial protocol NCT06016842 sponsored by Ipsen in Gastroenterology, Hepatology, and Renal, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-08-31 Enrollment: 276 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06016842
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)276 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06016842
Protocol FieldVerified Registry Value
NCT IdentifierNCT06016842
Consolidated Lead SponsorIpsen
Therapeutic Condition CohortGastroenterology, Hepatology, and Renal
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment276 participants (ESTIMATED)
Registered Start Date2023-08-31
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Gastroenterology, Hepatology, and Renal Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI